Compound class:
Synthetic organic
Comment: The CF3-substituted 1,3, oxazine 89 was found by Roche to be an orally active BACE1 inhibitor with an excellent PD profile in mice and a long lasting Aβ40/42 reduction in the CSF of rats[1] 13 PDB structures have been submitted and one of the series may enter clinical development
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Enzymatic potency was strongly affected by fluorines introduced into the oxazine headgroup. A down configured CF3 group in 89 improved the binding affinity considerably (IC50 = 0.012 μM) compared to unsubstituted 1b (IC50 = 0.051 μM). This compound 89 showed dose-dependent inhibition of brain Aβ40 production in mice at 4 h oral post dose and time-dependent inhibition of CSF Aβ40/42 production in rats after an oral dose of 1 mg/kg.[1] |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|